In this article, we are going to take a look at where Inari Medical, Inc. (NASDAQ:NARI) stands against other firms post strong gains amid Wall Street bloodbath. Wall Street’s main indices closed ...

Inari Medical Background Information (This ... FDA and CE Mark approved for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA and CE Mark approved for ...

Canaccord downgraded Inari Medical (NARI) to Hold from Buy with a price target of $80, up from $74, after Stryker (SYK) entered into a definitive agreement to acquire Inari in cash for $80 per share.

About Inari Medical, Inc., iRhythm Technologies and Inc. Inari ... and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large ...

Inari Medical’s top-line growth is primarily driven by its ClotTriever and FlowTriever products that target patients with venous thromboembolism (VTE) (with significant growth opportunities ...

It delivered a trailing four-quarter average earnings surprise of 24.77%. Inari Medical’s top-line growth is primarily driven by its ClotTriever and FlowTriever products that target patients with ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In the PEERLESS trial (PEERLESS; 32 Down), the difference was driven by less clinical deterioration and/or bailout as well as less use of intensive care for those treated with the FlowTriever system ...

Some of the key products of Veiva Scientific’s portfolio are Impella (Heart Pump for severe heart failure), IVUS-NIRS (Dual Modality Vascular Imaging), FlowTriever (Mechanical Thrombectomy device for ...

Inari Medical Inc is a medical device company ... vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism ...